Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Arbutus Says US Lifts Clinical Hold on AB-101 Hepatitis B Drug

Arbutus Says US Lifts Clinical Hold on AB-101 Hepatitis B Drug

MT newswireMT newswire2026/10/22 12:10
08:10 AM EDT, 10/22/2026 (MT Newswires) -- Arbutus Biopharma (ABUS) said Thursday the US Food and Drug Administration lifted a clinical hold on its AB-101 treatment for hepatitis B, letting the company run further trials of the drug in the country. AB-101 is a pill designed to switch on the body's immune response against the hepatitis B virus by blocking a protein called PD-L1, the company said. In a phase 1a/1b study, the drug was generally well tolerated, with strong target binding in seven chronic hepatitis B patients and a drop in virus surface protein in two patients at the 30 milligram dose, Arbutus said. Shares of the company were up 2.4% in Thursday premarket activity.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Ming-Chi Kuo: Google reduces next year's Broadcom-designed TPU shipments by 20% and plans to increase MediaTek's share

Renowned Apple and supply chain analyst Ming-Chi Kuo pointed out that Google has reduced the 2027 shipment volume of the TPU 8i series, designed by Broadcom, by about 1 million units, while planning to increase its procurement of the TPU 8t, designed by MediaTek. This move reflects that, limited by power and supply chain constraints, Google is prioritizing its computing resources towards the development of cutting-edge models.

华尔街见闻•2026/11/21 12:01
Ming-Chi Kuo: Google reduces next year's Broadcom-designed TPU shipments by 20% and plans to increase MediaTek's share